The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market […]

Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,

The business model for off-patent medicine is undergoing a forced evolution. For four decades, the Hatch-Waxman Act provided a predictable

The pharmaceutical sector operates on a punishing mathematical divide. In 2024, generic and biosimilar medicines filled 90% of all prescriptions

The Convergence of Federal Exclusivity and Public Health Necessity The pharmaceutical industry operates on a fundamental tension between two opposing

Reclaiming Revenue in the Patent Cliff The pharmaceutical industry faces a contraction of unprecedented scale. Between 2025 and 2030, nearly

Pharmaceutical revenue is a melting ice cube. Between 2025 and 2030, the global industry faces a wave of patent expirations

The pharmaceutical industry is currently moving through the most concentrated period of exclusivity loss in its history. Between 2025 and

Introduction: From Herbal Roots to a Global Vanguard The history of the Japanese pharmaceutical industry presents a compelling and instructive